Previous Article | Next Article ![]()
Infection and Immunity, April 2000, p. 1899-1904, Vol. 68, No. 4
Department of Medicine, University of Kansas
Medical Center, Kansas City, Kansas 66160,1
and Office of Research Administration, Kansas City,
Missouri 641112
Received 15 July 1999/Returned for modification 20 September
1999/Accepted 22 December 1999
In general there is a poor correlation between serum
lipopolysaccharide (LPS; the biologically active constituent of
endotoxin) levels and mortality in septic patients. The objective of
this study was to determine if chemical, structural, or biological differences among LPS from different clinical isolates of gram-negative bacteria might explain this discrepancy. LPS preparations were made
using the hot phenol-water extraction method from eight clinical isolates of gram-negative bacteria. As a percentage of the total weight
of the LPS, the phosphate content ranged from 3.0 to 13.8% (average,
6.7 ± 3.6%), and the 2-keto-3-deoxyoctonate content ranged from
1.9 to 27.4% (average, 8.9 ± 8.5%). These values were not
dissimilar to those obtained for a reference endotoxin. In a standard
measure of LPS activity, the Limulus amoebocyte lysate assay, there was approximately a twofold difference between the least
and most active preparations. The two preparations with the greatest
difference in their ability to elicit the secretion of tumor necrosis
factor alpha from a mouse peritoneal macrophage cell line were similar
in lethality when administered to mice sensitized to the effects of LPS
by D(+)-galactosamine. These relatively minor differences
in LPS activity seem unlikely to explain the generally observed
discrepancy between serum endotoxin levels and mortality in patients
with gram-negative sepsis.
It is currently estimated that
500,000 cases of sepsis occur in the United States each year. Half of
these are caused by gram-negative rods, and septic shock occurs in 50 to 60% of these cases (reviewed in reference 26).
The mortality rate remains high despite the use of intensive care units
and effective, broad-spectrum antibiotics. Bacterial lipopolysaccharide
(LPS; the biologically active constituent of endotoxin) from
gram-negative organisms is now well recognized to be a potent microbial
toxin that has been postulated to play a critical role in the
initiation of the proinflammatory events that contribute to the
pathogenesis of this disease. The pathophysiologic mechanism(s)
responsible for this illness are thought to result from the
noncytotoxic interaction of LPS with host inflammatory mediator cells
following its release from the bacterial outer cell membrane, resulting
in the production of multiple proinflammatory cytokines, reactive
oxygen and nitrogen intermediates, and bioactive lipids. The resultant
systemic inflammatory response is thought to lead to multiorgan failure
and often death (reviewed in references 14, 26, and
32).
A significant component of the experimental evidence supporting a
relationship between endotoxin and sepsis derives from studies in which
the administration of purified endotoxic LPS to experimental animals or
human volunteers reproduces many of the clinical symptoms seen in
patients with gram-negative sepsis. More recently, correlative data
from in vitro, ex vivo, and in vivo studies using viable intact
gram-negative microorganisms all provide strong indications that the
production of cytokines depends, to at least some extent, on the degree
to which various antibiotics induce the release of LPS from
gram-negative bacteria (3, 5, 6, 15, 29). Furthermore, the
amount of LPS released is now recognized to depend, at least in part,
on the differential binding of various The studies presented here have been designed to test the hypothesis
that LPS derived from clinical bacterial isolates is not uniform in its
biological potential to induce a proinflammatory response in vitro.
This hypothesis contrasts with the generally accepted underlying
assumption made in most studies that LPS derived from different
microbiological sources is of equal potency in biological systems.
There exists at least some evidence to support a diversity of LPS
biological activity, based upon observations that LPS activity can vary
substantially depending upon both the type of organism and the method
by which the LPS is extracted (23), the presence of outer
membrane proteins in association with the LPS (22), the
specific subunit composition of the LPS (i.e., presence of O-antigen
subunits) (33), and the presence of O-antigen carbohydrates
that are linked to the LPS (24). To date, these findings
have not been extended to the full range of microorganisms usually
encountered in clinical gram-negative bacterial sepsis.
An understanding of the range of biological diversity among the LPS of
clinical isolates of gram-negative bacterial is clearly a necessary
prerequisite to rational interpretation of the results of clinical
endotoxin-cytokine assays in septic patients. To address these issues,
we have undertaken a comprehensive series of studies in which LPS has
been extracted and purified from a variety of clinical isolates of
gram-negative bacteria. These various LPS have then been compared to
one another in a variety of standard in vitro and in vivo assays that
have traditionally been utilized to assess LPS biological activity.
Qualitative structural analyses were carried out using silver staining
after fractionation of LPS subunits using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Biological
activity in vitro was assessed by the quantitative Limulus
amoebocyte lysate assay and by the ability of the LPS preparations to
initiate the secretion of tumor necrosis factor alpha (TNF- Clinical isolates of gram-negative microorganisms.
Eight
clinical isolates of gram-negative microorganisms representing four
major genera commonly encountered in gram-negative infections (7,
8, 25) were obtained from the clinical pathology laboratory at
the University of Kansas Medical Center. These included two blood
isolates each of Citrobacter diversus, Escherichia
coli, and Serratia marcescens and one sputum and one urine isolate of Proteus mirabilis. All cultures were grown
in Trypticase soy broth to late log phase, harvested by centrifugation, and washed several times in sterile saline, and the LPS was extracted as described below. (Three isolates of Klebsiella sp. were
also selected. LPS preparations from these isolates were analyzed by SDS-PAGE and silver staining as described below, but results of other
analyses for the Klebsiella LPS preparations are not
included here because of a concern of substantial contamination of the Klebsiella LPS preparations with capsular polysaccharide.)
Extraction and purification of LPS.
The standard hot
phenol-water extraction method described by Westphal and Luderitz
(34, 35) was used to extract LPS from approximately 5 to
10 g (wet weight) of bacteria. The late-log-phase bacteria were
sedimented by centrifugation and then suspended in pyrogen-free
distilled water to a concentration of approximately 1010
CFU/ml. Bacteria were extracted two times with 90% aqueous phenol at
68°C, and the combined aqueous extracts were then dialyzed extensively against double-distilled H2O at 4°C and
lyophylized. Nucleic acids were removed by reconstitution of the
LPS-enriched extracts to 10 mg/ml in 0.1 M acetate buffer with 0.02%
MgSO4 and 0.4% chloroform and digestion with RNase (0.4 mg/ml; Sigma Chemical, St. Louis, Mo.) and DNase (20 µg/ml; Sigma) by
incubation at 37°C overnight. Contaminating protein was then removed
by the addition of proteinase K (20 µg/ml; Sigma) in 0.1 M Tris (pH
8.0), followed by heating at 60°C for 1 h and then incubation
overnight at 37°C. Enzyme-digested LPS samples were then dialyzed
extensively against multiple changes of deionized H2O. The
resulting purified LPS was lyophilized, dried over
P2O5 (Sigma), reconstituted in pyrogen-free
distilled water at 1.0 mg/ml, and stored in aliquots at Analytical procedures.
Studies to characterize common
chemical constituents of the core oligosaccharide-lipid A were carried
out by using standard analytical procedures. Phosphate content was
determined by the colorimetric method of Ames and Dubin (1);
2-keto-3-deoxyoctonate (KDO) was determined according to the
thiobarbituric acid method of Karkhanis et al. (17). Protein
contamination was estimated by using a Coomassie Protein Reagent Kit
(Pierce, Rockford, Ill.).
SDS-PAGE and silver staining of LPS.
SDS-PAGE and LPS silver
staining were performed as described by Tsai and Frasch
(31). A modified Laemmli SDS-PAGE system was used with the
Mini-Protean II gel apparatus (Bio-Rad, Hercules, Calif.) and
1.0-mm-thick gels.
LAL assays.
Limulus amoebocyte lysate (LAL) assays
were carried out using a chromogenic assay (the QCL 1000 Kit purchased
from BioWhittaker, Walkersville, Md.). The kit included vials of
standard LPS (E. coli O111:B4) containing a defined number
of endotoxin units (EU). The standard was reconstituted in pyrogen-free
distilled H2O. A standard curve ranging from 0 to 1.0 EU/ml
was constructed for each assay by plotting the optical density at 410 nm (OD410) versus EU per milliliter. Sample LPS
preparations were assayed over a range of 0.01 to 0.1 ng/ml, and
concentration was plotted against OD410. From the standard
curve, the OD410 corresponding to 0.5 EU/ml was determined.
This value was substituted into the formula for the line describing the
sample LPS to determine the concentration (in nanograms per milliliter)
of sample LPS corresponding to 0.5 EU/ml. The EU/nanogram values for
each LPS were calculated from these data. Each LPS was assayed three
times. Standards and samples were analyzed in duplicate, and absorption
was measured at 410 nm by using a Dynatech 5000 microplate reader.
Secretion of TNF- Mouse lethality studies.
CF-1 outbred female mice, 8 to 10 weeks of age, were purchased from Sasco (Kingston, N.Y.) and were
maintained in the University of Kansas Medical Center AALAC-accredited
animal facility for 5 to 10 days before use. Mice were sensitized to
the effects of LPS by the intraperitoneal injection of
D-galactosamine (Sigma) (30 mg in 0.4 ml of pyrogen-free
H2O per 25-g mouse) with or without LPS exactly according
to the method of Galanos et al. (10, 11). Mortality was
recorded 24 h after injection. The 50% lethal dose (LD50) was determined by the method of Reed and Muench
(27).
Extraction and chemical characterization of LPS from clinical
isolates of gram-negative organisms.
LPS was extracted from eight
clinical isolates of gram-negative bacteria using the standard hot
phenol method of Westphal et al. (34, 35). Yields of between
10 and 20 mg of LPS were obtained from about 5 g (wet weight) of
bacterial pellets. Commercially prepared LPS from E. coli
O111:B4 was included in these studies as a reference standard.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Comparable Endotoxic Properties of Lipopolysaccharides Are
Manifest in Diverse Clinical Isolates of Gram-Negative
Bacteria
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactam antibiotics to
selective penicillin-binding proteins (3, 15). Attempts to
correlate circulating levels of LPS and/or cytokine levels with
observed mortality in patients with gram-negative sepsis, however, have
to date failed to provide an overall convincing case for cause and
effect (4, 9, 13, 19, 20, 30). This apparent discrepancy may
well be the result of an unappreciated variability in the biological
activity and/or chemical structure of the LPS present in clinical
bacterial isolates, as well as of differences in its release caused by
different kinds of antibiotic treatment. Under such circumstances, it
would be virtually impossible to differentiate the pathophysiologic
potential of a given endotoxin level detected in the circulation with a
projected outcome of a systemic inflammatory episode.
) from a
macrophage-like cell line. The in vivo potency of LPS was assessed
using a sensitive mouse model of lethality.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C. LPS
from E. coli O111:B4 prepared by phenol-water extraction was
obtained from List Biologicals (Campbell, Calif.). "Rough" or
R-chemotype LPS from Neisseria meningitidis 6275 was kindly provided by C. M. Tsai, Food and Drug Administration, Rockville, Md.
from LPS-stimulated mouse macrophages.
J774A.1 cells, a mouse macrophage cell-like line (American Type Culture
Collection, Rockville, Md.) were cultured in canted neck flasks in RPMI
1640 medium (Gibco, Grand Island, N.Y.) supplemented with 4 mM
glutamine (Sigma), penicillin (100 U/ml; Sigma), and streptomycin (100 µg/ml; Sigma) and 10% heat-inactivated (56°C, 30 min) fetal bovine
serum (endotoxin content of <0.06 ng/ml; Sigma) in a humidified
incubator at 37°C with 5% CO2. Adherent cells were
removed with a rubber policeman and used to make a suspension of
105 cells/ml in RPMI. Then, 0.5-ml aliquots were
distributed to the wells of a 48-well tissue culture plate and allowed
to adhere overnight. The cells were then stimulated with the purified
LPS from the various clinical isolates or the standard E. coli O111:B4 LPS (range, 0.5 to 20 ng/ml) for 15 h. Mouse
TNF-
was measured in the supernatants by enzyme immunoassay
(Genzyme, Cambridge, Mass.).
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Phosphate, KDO, and protein contents of various
LPS preparationsa
Characterization of LPS subunit composition.
It is well
recognized that purified LPS from most strains of gram-negative
bacteria is heterogeneous with respect to the composition of individual
LPS subunits that comprise the LPS macromolecule. Evidence for
heterogeneity is readily detected by analysis by using SDS-PAGE,
followed by silver staining to detect individual LPS subunits. The
silver-staining profiles of the various LPS subunit patterns from the
E. coli standard and the clinical isolates are shown in Fig.
1. Of interest, the majority of the LPS
manifest the typical ladder-like pattern characteristic of S-LPS.
However, two isolates of Klebsiella pneumoniae (lanes 12 and
13) have silver-staining patterns that strongly suggest an absence of
significant amounts of O antigen-containing LPS subunits. Therefore,
these would be designated as chemically incomplete or rough (R) forms
of LPS. Even within species, it is clear that differences in the actual subunit patterns can be readily detected (e.g., compare lanes 2 and 3 and lanes 5 and 6). Thus, we conclude that, from a physical-chemical perspective, the LPS preparations, while similar, manifest unique differences from one another.
|
Activity of LPS preparations in the LAL assay. The LAL assay is recognized as one of the most sensitive detection systems for determining the presence of LPS, and it is generally accepted as the method of choice for determining the presence of LPS in parenterally administered drugs and of endotoxin in body fluids. Since this assay has been used to establish correlations with outcome in cases of sepsis, it was felt to be important to use this measure of activity to assess the relative potency of the different LPS preparations.
The LAL activity of the various sample LPS preparations was determined in chromogenic LAL assays in comparison to a known standard. The standard LPS was provided by the LAL supplier and consisted of vials of E. coli O111:B4 LPS containing a defined number of EU. Sample LPS preparations were compared to the standard curve obtained with LPS from E. coli O111:B4, and the data are expressed in EU per nanograms of sample LPS as explained in Materials and Methods. Investigators experienced with this assay recognize the considerable variation inherent to it. This was our experience as well. Although the technical performance of the assay was excellent, as suggested by the R-square values for the typical standard curves used in these assays (average R square value, 0.99; range, 0.96 to 1.0 [± 0.015]), there was considerable variation in the slope of the standard curve from one assay to the other (average slope, 1.0; range, 0.69 to 1.4 [± 0.32]). For a value of 0.5 OD units, the corresponding standard curve values of EU per milliliter would vary by as much as 1.7-fold. For each sample LPS, the average fold difference among the three determinations was 1.8 (range, 1.2 to 2.4), and this is reflected in the standard error (see below and Fig. 3). Thus, we conclude that there may be an approximately twofold variation in LAL activity for a given LPS preparation from one assay to another. Figure 2 shows typical dose-response curves obtained for three LPS preparations. These dose-activity profiles indicate that the assay is linear over the range of LPS concentrations studied. Figure 3 shows a summary of the results for each LPS preparation (three determinations per preparation). LPS from S. marcescens 2 had the lowest LAL activity (10.7 EU/ng [±1.9]), and E. coli O111:B4 had the highest (24.6 EU/ng [±5.1]). This represents a 2.3-fold difference between the least and most potent LPS preparations as determined in this assay. The average values by genus were: E. coli, 17.5 EU/ng (±6.2); P. mirabilis, 18.0 EU/ng (±9.2); C. diversus, 14.8 EU/ng (±2.3); and S. marcescens, 12.3 EU/ng (±2.4). Given the variability of the LAL assay as described above, these differences do not constitute a measurable degree of biologic variability.
|
|
Secretion of TNF-
from LPS-stimulated mouse macrophages.
In
the past decade, a large number of studies have strongly implicated
proinflammatory cytokines, in particular, TNF-
, as a potentially
important mediator of the septic response during gram-negative
infections. We therefore carried out detailed quantitative assessments
of LPS-induced TNF-
secretion. As an in vitro measure of their
inflammatory potential, we evaluated the ability of selected LPS with
different LAL bioactivities to stimulate the release of the
inflammatory cytokine, TNF-
, from the mouse macrophage-like J774A.1
cell line, and we compared these results to their potency in the LAL
assay (Table 2). As shown by the data in
this table, there is clearly a large variability in the amount of
TNF-
produced by the different LPS preparations. Of the five LPS
preparations assayed for their ability to stimulate the release of
TNF-
, E. coli 2 and S. marcescens 1 had the
least activity in the LAL assays. However, E. coli 2 was the
most effective at releasing TNF-
from J774 cells, and S. marcescens 1 was the least effective. Therefore, we conclude that
the ability of an individual LPS preparation to induce the secretion of
TNF-
from J774A.1 cells does not necessarily correlate to a precise
1:1 ratio with its potency in the LAL assay.
|
Determination of LD50 values.
In earlier published
experiments to assess the lethal effects of LPS in mice, Galanos et al.
(11) have shown that, in contrast to LPS alone, simultaneous
intraperitoneal injection of D-galactosamine with LPS
renders the mice up to 10,000-fold more sensitive to LPS. This effect
is mediated by an increased sensitivity of the mouse to TNF-
elaborated by LPS-stimulated host inflammatory cells in vivo
(10). Therefore, this is a useful model for examining the
relationship between the in vitro results of LPS-induced TNF-
release from J774A.1 cells and the in vivo effects of LPS on mice. We
have included in our analysis four of the five LPS preparations for
which TNF-
inducing ability was assayed. As a standard of comparison, LPS from E. coli O111B:4 was determined to have
an LD50 value of 11. E. coli 2, with the
greatest TNF-
inducing ability, had an LD50 value of 12, while S. marcescens 1, with the least TNF-
inducing
ability, had an LD50 value of 17. The LD50
values for LPS from E. coli 2 and P. mirabilis 2 (with, respectively, the least and greatest LAL activity of the five
LPS preparations assayed for TNF-
inducing ability) were 12 and 15. These are considered minor differences for this assay. In this small
sample, LPS preparations with differing activity in the TNF-
producing and LAL assays have virtually identical toxic effects in mice sensitized to LPS by D-galactosamine.
| |
DISCUSSION |
|---|
|
|
|---|
In order to investigate the possibility that differences in the inflammatory properties of LPS from gram-negative bacteria might account for the often observed discrepancy between detected levels of serum LPS in patients with sepsis and clinical outcome, we have tested the hypothesis that LPS from diverse clinical isolates of gram-negative bacteria differ significantly in several standard measures of LPS activity and LPS-induced inflammation. Our results show that there is little evidence to suggest that there are substantial differences among such LPS preparations when extracted from clinical isolates of bacteria using standard chemical methods.
Specifically, we were unable to detect large differences in the
activity of the LPS preparations in chromogenic Limulus
amoebocyte assays, a standard measure for detecting the presence of LPS
in serum. Moreover, the differences determined in the ability of these
preparations to elicit the release of TNF-
, thought to be a key
mediator of inflammation, from macrophage-like cells did not correlate
with the in vivo model of lethality in which mice are sensitized to
TNF-
produced in response to LPS. Because the differences among the
LPS preparations in the biological parameters studied in these
experiments are small, they are not useful in understanding the
apparent discrepancy between serum endotoxin levels and mortality.
The modified hot phenol-water extraction method of Luderitz and Westphal (34) worked well in purifying LPS from the clinical isolates as demonstrated by the low level of protein and nucleic acid contamination. In general, the phosphate and KDO contents of the LPS preparations were within the expected range, based on a comparison to other LPS. The silver-staining patterns of the LPS preparations demonstrated the typical ladder-like pattern characteristic of S-LPS. Thus, these preparations were suitable for the studies performed here. However, as a percentage of the total weight, two LPS preparations had KDO compositions that were substantially higher than the rest: C. diversus 1 and the standard LPS, E. coli O111:B4 (27.4 and 19.0% compared to a mean of 4.9% for the other six LPS preparations). The reasons for and significance of this finding are not clear. However, it is probable that other deoxy sugars present in the LPS were not adequately corrected for in the chemical analysis; nevertheless, since neither of the LPS preparations with a relatively high KDO content was characterized by especially high or low activity in any of the studies done here, we have not placed more significance upon this finding.
As pointed out above, it is generally accepted that the LAL assay is one of the most sensitive methods for detecting the presence of LPS, and it has therefore been the primary means for detection of LPS in plasma from patients with sepsis. However, it is not known if LPS activity in this assay varies among pathogenic strains of gram-negative bacteria isolated from clinical specimens or if activity in this assay correlates with the ability of LPS to induce inflammation or cause death. Within the limits of reproducibility of the assay, we were unable to detect a measurable difference in LAL activity among the eight LPS preparations studied.
TNF-
is considered a leading mediator of the septic response induced
by gram-negative organisms during infection. Therefore, as a measure of
their in vitro inflammatory potential, we chose to compare the ability
of different LPS preparations to induce the release of TNF-
from a
mouse macrophage-like cell line. We did not identify a strong positive
1:1 correlation between activity of individual LPS preparations in the
LAL assay and the in vitro TNF-
induction studies. For example
P. mirabilis 2 had twice the activity of E. coli
2 in the LAL assay but produced one-third less TNF-
. Subtle
relationships between LAL activity and TNF-
inducing ability might
be obscured by variations inherent to the LAL assay and TNF-
studies.
CF-1 mice sensitized to LPS with D-galactosamine according
to the method of Galanos et al. (10, 11) were used to
determine if differences existed in the toxic properties of the
different LPS preparations. Of the five LPS preparations tested for
TNF-
inducing capacity, those with the largest differences in LAL
activity (E. coli 2 versus P. mirabilis 2)
manifested only minor differences in LD50. Of these five
LPS, the two preparations with the greatest difference in TNF-
inducing ability (E. coli 2 and S. marcescens 1)
also demonstrated minor differences compared to each other. Therefore,
we were unable to detect meaningful differences in lethality among the
LPS preparations with the greatest disparity in both LAL activity and
TNF-
inducing ability by using a murine model of LPS lethality.
However, these findings are not inconsistent with the results recently
published by Amura et al. (2), who reported a lack of
correlation between in vivo lethality of LPS and in vitro ability to
induce TNF-
production.
Although we were unable to define a difference in the bioactivity or toxicity among the LPS preparations studied in these experiments, it would nevertheless be premature to conclude that differences do not exist among LPS produced by gram-negative bacteria in clinical situations. This is because the LPS prepared for these studies was a chemically extracted and purified preparation virtually devoid of cell-associated membranes, proteins, and nucleic acids. Although this method of preparation has been a powerful tool in the study of LPS, the direct relevance of such preparations to the in vivo setting is not well known. The in vivo release of LPS may occur by a variety of mechanisms, including natural shedding of LPS from "blebs" formed on the surface of bacteria and through the process of bacterial lysis mediated either by humoral factors such as complement and antibody or by exogenous factors such as antibiotics. Indeed, antibiotics that inhibit penicillin-binding protein 3 result in disordered cell wall synthesis, elongation of bacteria into filamentous forms, a substantial increase in cell biomass, and subsequent release of large quantities of LPS from gram-negative bacteria (reviewed in reference 16). The precise composition and structure of antibiotic-released LPS is unknown, but it is clear that relevant questions should include whether other cellular components, such as proteins, lipids, or other cell wall and outer membrane structures might be associated with released LPS and also what role they might play in the inflammatory properties of such LPS preparations. For example, it is well established that isolation of LPS from gram-negative bacteria is often associated with coisolation of microbial outer membrane proteins, usually tightly bound to the LPS molecular complex (21). Further, the demonstrated biological activity of such proteins in stimulating cells of the immune-inflammatory system is well documented (12, 18, 22). Evidence from animal models of infection with gram-negative bacteria indicates that antibiotics which release greater quantities of LPS may result in higher mortality (5). Thus, there would appear to be a number of compelling reasons to explore in more detail the "natural state" of endotoxin generated under simulated situations likely to be operative in clinical sepsis.
Currently, there are few studies comparing the activity of LPS released
from bacteria following interaction with antibiotics and LPS chemically
extracted using the modified hot phenol-water method. The findings
reported here, therefore, demonstrating that there is little variation
between purified LPS of clinical isolates from different species,
provide a solid foundation upon which such questions can be addressed
experimentally. We are actively investigating this question by using
the clinical isolates of gram-negative bacteria used for the
experiments described here. By incubating these bacteria with different
-lactam antibiotics and isolating the LPS-associated subcellular
components released into the growth medium by filtration and
centrifugation, we will be able to compare the activity of
antibiotic-released LPS with the LPS prepared by hot phenol-water
extraction for the experiments reported here.
In summary, we have prepared LPS from clinical isolates of
gram-negative bacteria by using the modified hot phenol-water method and characterized them chemically, structurally, and physiologically. There were only small differences among these LPS preparations with
respect to their activity in the LAL assay, their ability to elicit the
secretions of TNF-
from a macrophage-like cell line, or their
toxicity in mice sensitized to the effects of LPS by
D-galactosamine. These differences are insufficient to
explain the lack of correlation between serum endotoxin levels and
mortality in sepsis.
| |
ACKNOWLEDGMENTS |
|---|
We would like to acknowledge the assistance of S. N. Vogel (Uniformed Services, University of the Health Sciences), A. S. Cross (University of Maryland), and S. M. Opal (Brown University) for guidance in these experiments. C. M. Tsai (Food and Drug Administration, Rockville, Md.) generously allowed us to use his laboratory for the SDS-PAGE and silver-staining procedures. Technical assistance was provided by Paula Worley, Rebecca Hegarty, and Eugene Gregory.
This work was supported by grants from the National Institutes of Health (AI23447, DCM, and an Institutional Development Award; Principal Investigator S. W. Russell, University of Kansas Medical Center) and in part through an unrestricted medical grant from Merck and Co. Inc., West Point, Pa.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7354. Phone: (913) 588-6035. Fax: (913) 588-6024. E-mail: mluchi{at}kumc.edu.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ames, B. N., and D. T. Dubin.
1960.
The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid.
J. Biol. Chem.
235:769-775 |
| 2. |
Amura, C. R.,
R. Silverstein, and D. C. Morrison.
1998.
TI: mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies.
Infect. Immun.
66:5372-5378 |
| 3. | Arditi, M., W. Kabat, and R. Yogev. 1993. Antibiotic-induced bacterial killing stimulates tumor necrosis factor-alpha release in whole blood. J. Infect. Dis. 167:240-244[Medline]. |
| 4. | Brandtzaeg, P., T. E. Mollnes, and P. Kierulf. 1989. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 160:58-65[Medline]. |
| 5. | Bucklin, S. E., and D. C. Morrison. 1995. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J. Infect. Dis. 172:1519-1527[Medline]. |
| 6. |
Dofferhoff, A. S.,
M. T. Esselink,
H. G. de Vries Hospers,
A. van Zanten,
V. J. Bom,
J. Weits, and E. Vellenga.
1993.
The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes.
J. Antimicrob. Chemother.
31:373-384 |
| 7. | Doran, T. I. 1999. The role of citrobacter in clinical disease of children: review. Clin. Infect. Dis. 28:384-394[Medline]. |
| 8. | Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244[Medline]. |
| 9. | Elin, R. J., R. A. Robinson, A. S. Levine, and S. M. Wolff. 1975. Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N. Engl. J. Med. 293:521-524[Abstract]. |
| 10. | Galanos, C., M. A. Freudenberg, T. Katschinski, R. Salomao, H. Mossmann, and Y. Kumazawa. 1992. Tumor necrosis factor and host response to endotoxin, p. 75-104. In J. L. Ryan, and D. C. Morrison (ed.), Bacterial endotoxic lipopolysaccharides: immunopharmacology and pathophysiology. CRC, Ann Arbor, Mich. |
| 11. |
Galanos, C.,
M. A. Freudenberg, and W. Reutter.
1979.
Galactosamine-induced sensitization to the lethal effects of endotoxin.
Proc. Natl. Acad. Sci. USA
76:5939-5943 |
| 12. |
Goodman, G. W., and B. M. Sultzer.
1979.
Endotoxin protein is a mitogen and polyclonal activator of human B lymphocytes.
J. Exp. Med.
149:713-723 |
| 13. | Hurley, J. C. 1992. Antibiotic-induced release of endotoxin: a reappraisal. Clin. Infect. Dis. 15:840-854[Medline]. |
| 14. | Ingalls, R. R., H. Heine, E. Lien, A. Yoshimura, and D. Golenbock. 1999. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect. Dis. Clin. North Am. 13:341-353[CrossRef][Medline]. |
| 15. | Jackson, J. J., and H. Kropp. 1992. Beta-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J. Infect. Dis. 165:1033-1041[Medline]. |
| 16. |
Jackson, J. J., and H. Kropp.
1996.
Differences in mode of action of -lactam antibiotics influence morphology, LPS release and in vivo antibiotic efficacy.
J. Endotoxin. Res.
3:201-218.
|
| 17. | Karkhanis, Y. D., J. Y. Zeltner, J. J. Jackson, and D. J. Carlo. 1978. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of gram-negative bacteria. Anal. Biochem. 85:595-601[CrossRef][Medline]. |
| 18. | Killion, J. W., and D. C. Morrison. 1988. Determinants of immunity to murine salmonellosis: studies involving immunization with lipopolysaccharide-lipid A-associated protein complexes in C3H/HeJ mice. FEMS Microbiol. Immunol. 1:41-53[Medline]. |
| 19. | Levin, J., T. E. Poore, N. S. Young, S. Margolis, N. P. Zauber, A. S. Townes, and W. R. Bell. 1972. Gram-negative sepsis: detection of endotoxemia with the limulus test, with studies of associated changes in blood coagulation, serum lipids, and complement. Ann. Intern. Med. 76:1-7. |
| 20. | Levin, J., T. E. Poore, N. P. Zauber, and R. S. Oser. 1970. Detection of endotoxin in the blood of patients with sepsis due to gram-negative bacteria. N. Engl. J. Med. 283:1313-1316. |
| 21. | Manthey, C. L., and S. N. Vogel. 1994. Elimination of trace endotoxin protein from rough chemotype LPS. J. Endotoxin Res. 1:84-89. |
| 22. |
Morrison, D. C.,
S. J. Betz, and D. M. Jacobs.
1976.
Isolation of a lipid A bound polypeptide responsible for "LPS-initiated" mitogenesis of C3H/HeJ spleen cells.
J. Exp. Med.
144:840-846 |
| 23. |
Morrison, D. C., and L. Leive.
1975.
Fractions of lipopolysaccharide from Escherichia coli O111B:4 prepared by two extraction procedures.
J. Biol. Chem.
250:2911-2919 |
| 24. | Morrison, D. C., S. W. Vukajlovich, J. L. Ryan, and J. Levin. 1987. Structural requirements for gelation of the Limulus amebocyte lysate by endotoxin. Prog. Clin. Biol. Res. 231:55-73[Medline]. |
| 25. | Pfaller, M. A., R. N. Jones, S. A. Marshall, S. L. Coffman, R. J. Hollis, M. B. Edmond, and R. P. Wenzel. 1997. Inducible ampC beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn. Microbiol. Infect. Dis. 28:211-219[CrossRef][Medline]. |
| 26. | Rangel-Frausto, M. S. 1999. The epidemiology of bacterial sepsis. Infect. Dis. Clin. North Am. 13:299-312[CrossRef][Medline]. |
| 27. | Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497. |
| 28. |
Rudbach, J. A.,
F. I. Akiya,
R. J. Elin,
H. D. Hochstein,
M. K. Luoma,
E. C. Milner,
K. C. Milner, and K. R. Thomas.
1976.
Preparation and properties of a national reference endotoxin.
J. Clin. Microbiol.
3:21-25 |
| 29. | Simon, D. M., G. Koenig, and G. M. Trenholme. 1991. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli. J. Infect. Dis. 164:800-802[Medline]. |
| 30. | Stumacher, R. J., M. J. Kovnat, and W. R. McCabe. 1973. Limitations of the usefulness of the Limulus assay for endotoxin. N. Engl. J. Med. 288:1261-1264. |
| 31. | Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119[CrossRef][Medline]. |
| 32. | van der, P., T., and S. J. van Deventer. 1999. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. 13:413-426[CrossRef][Medline]. |
| 33. | Vukajlovich, S. W., and D. C. Morrison. 1985. Activation of murine spleen cells by lipid A: negative modulation of lipid A mitogenic activity by O-antigen polysaccharide. J. Immunol. 135:2546-2550[Abstract]. |
| 34. | Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure, p. 83-91. In R. L. Whistler (ed.), Methods in carbohydrate chemistry. Academic Press, Inc., New York, N.Y. |
| 35. | Westphal, O., O. Luderitz, and F. Bister. 1952. Über die Extraktion von Bakterien mit Phenol/Wasser. Z. Naturforschung. B 7B:148-155. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»